FDA Approved: DEPAKOTE — Supplemental Application (AbbVie Inc.)

View source ↗

Summary

FDA approved a supplemental NDA for Depakote (divalproex sodium) submitted by AbbVie Inc.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Bipolar Disorder
• Epilepsy
• Migraine

Drugs mentioned

• DEPAKOTE (DIVALPROEX SODIUM)

Snippet

SUPPL AP for DEPAKOTE (DIVALPROEX SODIUM)